Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of "Hold" by Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $349.30.

A number of equities research analysts have recently weighed in on MEDP shares. Robert W. Baird cut their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday. Truist Financial reduced their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and dropped their price target for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday.

Medpace Trading Up 3.2 %

Shares of MEDP stock traded up $8.94 during mid-day trading on Tuesday, reaching $291.22. The stock had a trading volume of 1,419,454 shares, compared to its average volume of 338,215. The firm has a market capitalization of $8.80 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The stock's 50-day moving average price is $316.36 and its two-hundred day moving average price is $332.53. Medpace has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. During the same quarter in the prior year, the company posted $3.20 EPS. On average, equities research analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after acquiring an additional 29 shares during the period. Lindbrook Capital LLC lifted its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC boosted its position in Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. grew its stake in shares of Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after purchasing an additional 30 shares during the period. Institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.